Dr. Sylvia E. Rosas, MD

Dr. Rosas practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Rosas' NPI, 1568497600, was assigned on July 11, 2006. Dr. Rosas holds Massachusetts license 257012.

Dr. Rosas' primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Rosas' primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Rosas is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Rosas to 2 more dialysis centers, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosas practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Rosas' primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Rosas' licenses on file in 2 states: Massachusetts and Pennsylvania.

CMS data shows 427 Medicare services from Dr. Rosas across 7 procedure codes in 2024, for 166 Medicare patients. Medicare paid $30,189 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 166 Medicare patients who saw Dr. Rosas in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 40% are also on Medicaid. Their average risk score is 4.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosas' median patient age at 69, with 46% women.

In 2024, Dr. Rosas wrote 804 Medicare Part D claims for 123 patients. 88% of them were for generic drugs. CMS names the drug for 653 of them, across 16 drugs with 11 or more claims each, at $90,999 in total drug cost. In 2023, CMS named 735 claims across 19 drugs.

Dr. Rosas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosas as offering telehealth.

CMS Open Payments shows 119 general payments to Dr. Rosas from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 47% of the total. Sanofi and Genzyme US Companies paid the most, $24,724. It also lists 7 research payments totaling $25,276 from 2016 to 2025.